EA202091218A1 - Соли дифосфатфосфорамидата нуклеозидов в качестве противораковых соединений - Google Patents
Соли дифосфатфосфорамидата нуклеозидов в качестве противораковых соединенийInfo
- Publication number
- EA202091218A1 EA202091218A1 EA202091218A EA202091218A EA202091218A1 EA 202091218 A1 EA202091218 A1 EA 202091218A1 EA 202091218 A EA202091218 A EA 202091218A EA 202091218 A EA202091218 A EA 202091218A EA 202091218 A1 EA202091218 A1 EA 202091218A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nucleoside
- diposphatphosphoramidate
- salts
- anticancer compounds
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000002777 nucleoside Substances 0.000 title abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 title abstract 2
- 230000001093 anti-cancer Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- ADNNKJYMXXHRDR-UHFFFAOYSA-N aminophosphonic acid phosphono dihydrogen phosphate Chemical compound NP(O)(O)=O.OP(O)(=O)OP(O)(O)=O ADNNKJYMXXHRDR-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 abstract 1
- 229960000928 clofarabine Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720279.7A GB201720279D0 (en) | 2017-12-05 | 2017-12-05 | Anticancer compounds |
| PCT/GB2018/053525 WO2019110991A1 (en) | 2017-12-05 | 2018-12-05 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091218A1 true EA202091218A1 (ru) | 2020-09-14 |
Family
ID=60950385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091218A EA202091218A1 (ru) | 2017-12-05 | 2018-12-05 | Соли дифосфатфосфорамидата нуклеозидов в качестве противораковых соединений |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11560400B2 (enExample) |
| EP (2) | EP3720864B1 (enExample) |
| JP (1) | JP7268819B2 (enExample) |
| KR (1) | KR20200092980A (enExample) |
| CN (1) | CN111527098A (enExample) |
| AU (1) | AU2018379713A1 (enExample) |
| BR (1) | BR112020011221A2 (enExample) |
| CA (1) | CA3082269A1 (enExample) |
| CL (1) | CL2020001479A1 (enExample) |
| DK (1) | DK3720864T3 (enExample) |
| EA (1) | EA202091218A1 (enExample) |
| ES (1) | ES2910165T3 (enExample) |
| GB (1) | GB201720279D0 (enExample) |
| HR (1) | HRP20220451T1 (enExample) |
| IL (1) | IL274808B2 (enExample) |
| MA (2) | MA51007A (enExample) |
| MX (1) | MX2020005850A (enExample) |
| PH (1) | PH12020550728A1 (enExample) |
| PL (1) | PL3720864T3 (enExample) |
| PT (1) | PT3720864T (enExample) |
| SG (1) | SG11202004342TA (enExample) |
| WO (1) | WO2019110991A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20191461T1 (hr) | 2014-11-28 | 2019-11-15 | NuCana plc | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja |
| JP2020164521A (ja) * | 2019-03-29 | 2020-10-08 | 国立大学法人 長崎大学 | 抗ウィルス薬 |
| CN116768949B (zh) * | 2022-07-12 | 2026-03-03 | 南京工业大学 | 一种基于3’-脱氧腺苷经化学修饰改性的具有抗癌效应的化合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| GB0505781D0 (en) | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| WO2010135520A1 (en) | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
| GB201016855D0 (en) | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| ES2569185T3 (es) | 2011-03-01 | 2016-05-09 | Nucana Biomed Limited | Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer |
| WO2014124430A1 (en) * | 2013-02-11 | 2014-08-14 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
| TW201542581A (zh) | 2013-09-11 | 2015-11-16 | 艾默理大學 | 核苷酸與核苷治療組成物及其相關用途 |
| CN105646629A (zh) | 2014-11-25 | 2016-06-08 | 广州市恒诺康医药科技有限公司 | L-核苷类化合物及其应用 |
| HRP20191461T1 (hr) | 2014-11-28 | 2019-11-15 | NuCana plc | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja |
| WO2016099982A2 (en) * | 2014-12-15 | 2016-06-23 | Emory University | Phosphoramidates for the treatment of hepatitis b virus |
| WO2016106050A1 (en) | 2014-12-26 | 2016-06-30 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| WO2017106710A1 (en) | 2015-12-17 | 2017-06-22 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2017155923A1 (en) | 2016-03-07 | 2017-09-14 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201609602D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
-
2017
- 2017-12-05 GB GBGB1720279.7A patent/GB201720279D0/en not_active Ceased
-
2018
- 2018-12-05 HR HRP20220451TT patent/HRP20220451T1/hr unknown
- 2018-12-05 MX MX2020005850A patent/MX2020005850A/es unknown
- 2018-12-05 EA EA202091218A patent/EA202091218A1/ru unknown
- 2018-12-05 EP EP18819340.3A patent/EP3720864B1/en active Active
- 2018-12-05 US US16/769,635 patent/US11560400B2/en active Active
- 2018-12-05 BR BR112020011221-6A patent/BR112020011221A2/pt not_active IP Right Cessation
- 2018-12-05 SG SG11202004342TA patent/SG11202004342TA/en unknown
- 2018-12-05 EP EP21218125.9A patent/EP4043471A1/en not_active Withdrawn
- 2018-12-05 CA CA3082269A patent/CA3082269A1/en active Pending
- 2018-12-05 CN CN201880078576.6A patent/CN111527098A/zh active Pending
- 2018-12-05 DK DK18819340.3T patent/DK3720864T3/da active
- 2018-12-05 JP JP2020530585A patent/JP7268819B2/ja active Active
- 2018-12-05 PT PT188193403T patent/PT3720864T/pt unknown
- 2018-12-05 ES ES18819340T patent/ES2910165T3/es active Active
- 2018-12-05 WO PCT/GB2018/053525 patent/WO2019110991A1/en not_active Ceased
- 2018-12-05 AU AU2018379713A patent/AU2018379713A1/en not_active Abandoned
- 2018-12-05 MA MA051007A patent/MA51007A/fr unknown
- 2018-12-05 MA MA051006A patent/MA51006A/fr unknown
- 2018-12-05 KR KR1020207016514A patent/KR20200092980A/ko not_active Withdrawn
- 2018-12-05 PL PL18819340T patent/PL3720864T3/pl unknown
-
2020
- 2020-05-20 IL IL274808A patent/IL274808B2/en unknown
- 2020-05-28 PH PH12020550728A patent/PH12020550728A1/en unknown
- 2020-06-03 CL CL2020001479A patent/CL2020001479A1/es unknown
-
2022
- 2022-12-16 US US18/083,089 patent/US20230192750A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP7268819B2 (ja) | 2023-05-08 |
| CL2020001479A1 (es) | 2020-12-18 |
| EP4043471A1 (en) | 2022-08-17 |
| AU2018379713A1 (en) | 2020-07-23 |
| DK3720864T3 (da) | 2022-04-11 |
| HRP20220451T1 (hr) | 2022-05-27 |
| PT3720864T (pt) | 2022-04-06 |
| KR20200092980A (ko) | 2020-08-04 |
| PH12020550728A1 (en) | 2021-02-15 |
| IL274808B2 (en) | 2023-08-01 |
| GB201720279D0 (en) | 2018-01-17 |
| US20210171566A1 (en) | 2021-06-10 |
| IL274808B1 (en) | 2023-04-01 |
| EP3720864B1 (en) | 2022-01-05 |
| CN111527098A (zh) | 2020-08-11 |
| IL274808A (en) | 2020-07-30 |
| MA51007A (fr) | 2020-10-14 |
| US20230192750A1 (en) | 2023-06-22 |
| MA51006A (fr) | 2020-10-14 |
| BR112020011221A2 (pt) | 2020-11-17 |
| MX2020005850A (es) | 2020-09-07 |
| JP2021505578A (ja) | 2021-02-18 |
| EP3720864A1 (en) | 2020-10-14 |
| PL3720864T3 (pl) | 2022-05-02 |
| ES2910165T3 (es) | 2022-05-11 |
| WO2019110991A1 (en) | 2019-06-13 |
| SG11202004342TA (en) | 2020-06-29 |
| US11560400B2 (en) | 2023-01-24 |
| CA3082269A1 (en) | 2019-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120839T1 (el) | Ακυκλικοι νουκλεοζιτικοι φωσφονικοι διεστερες | |
| SA523440283B1 (ar) | مركبات مضادة للأورام | |
| JOP20200110A1 (ar) | متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات | |
| CO2017003960A2 (es) | Métodos para tratar infecciones por el virus filoviridae | |
| CL2018003404A1 (es) | Derivados del nucleósido de fosforamidato como agentes anticancer. | |
| TW201613859A (en) | Analogs of PRIDOPIDINE, their preparation and use | |
| EA201692511A1 (ru) | Комбинированное лечение ингибиторами глутаминазы | |
| SA519410795B1 (ar) | تخليق مشتقات فوسفات | |
| EA201692312A1 (ru) | Продукты гемцитабина | |
| MX2022012013A (es) | Composiciones y metodos para transduccion de tumores. | |
| MX385837B (es) | Terapia de combinacion. | |
| MX2018007782A (es) | Forma cristalina de gemcitabina. | |
| MX377528B (es) | Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer. | |
| MY178745A (en) | Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them | |
| PH12020550728A1 (en) | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds | |
| EA202192660A1 (ru) | Противораковые соединения | |
| HK40062992A (en) | Salt of triphosphate phosphoramidates of nucleotides as anticancer compounds | |
| EA202090269A2 (ru) | Продукты гемцитабина | |
| IN2014MU00625A (enExample) | ||
| UA98248U (uk) | Спосіб подолання лікарської резистентності до протипухлинних препаратів |